Brokerages Set Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Target Price at $44.00

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been assigned an average rating of “Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and three have issued a strong buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $44.00.

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Jefferies Financial Group began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Finally, Wedbush upped their target price on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, July 30th.

Damora Therapeutics, Inc. Common Stock Trading Down 0.1%

Shares of NASDAQ:DMRA opened at $28.14 on Wednesday. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.45 and a twelve month high of $38.33. The company has a market cap of $1.74 billion, a PE ratio of -8.35 and a beta of 1.46. The company’s 50 day moving average is $29.41 and its 200 day moving average is $26.89.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.06. Equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DMRA. Ikarian Capital LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $6,574,000. Jain Global LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at approximately $2,774,000. Remedium Capital Partners LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $2,772,000. Boothbay Fund Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,204,000. Finally, Geode Capital Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $266,000. 14.20% of the stock is owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.